|

A2B543 Clinical Trials

1 actively recruiting trial across 1 location

Also known as: Tmod CAR T-cell Therapy

Pipeline

Phase 1/2: 1

Top Sponsors

  • A2 Biotherapeutics Inc.1

Indications

  • MESOM1
  • Ovary Cancer1
  • Mesothelioma, Malignant1
  • CRC1
  • Non-Small Cell Squamous Lung Cancer1

Gilbert, Arizona1 trial

A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

Banner Health

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.